Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvin Tan

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivoJayne Murray, Emanuele Valli, Denise M T Yu, et al.
Journal of Medicinal Chemistry|March 10, 2026
Sulfonyl Anthranilic Acid Analogues Display Pan-Serotype Anti-Dengue Activity by Downregulating the Expression of Ribosomal Proteins Encoded by 5'-Terminal Oligopyrimidine Motif-Containing mRNAChin Piaw Gwee, Tommaso Felicetti, Kitti Wing Ki Chan, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
European Urology Oncology|February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUPMartin R Stockler, Andrew J Martin, Ian D Davis, et al.
Annals of the Academy of Medicine, Singapore|November 6, 2025
Singapore consensus statements on the management of obstructive sleep apnoeaLeong Chai Leow, Chuen Peng Lee, Sridhar Venkateswaran, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivoJayne Murray, Emanuele Valli, Denise M T Yu, et al.
Journal of Medicinal Chemistry|March 10, 2026
Sulfonyl Anthranilic Acid Analogues Display Pan-Serotype Anti-Dengue Activity by Downregulating the Expression of Ribosomal Proteins Encoded by 5'-Terminal Oligopyrimidine Motif-Containing mRNAChin Piaw Gwee, Tommaso Felicetti, Kitti Wing Ki Chan, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
European Urology Oncology|February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUPMartin R Stockler, Andrew J Martin, Ian D Davis, et al.
Annals of the Academy of Medicine, Singapore|November 6, 2025
Singapore consensus statements on the management of obstructive sleep apnoeaLeong Chai Leow, Chuen Peng Lee, Sridhar Venkateswaran, et al.
Pageof 6